CN1188409A - Antifungal agent - Google Patents
Antifungal agent Download PDFInfo
- Publication number
- CN1188409A CN1188409A CN96194503A CN96194503A CN1188409A CN 1188409 A CN1188409 A CN 1188409A CN 96194503 A CN96194503 A CN 96194503A CN 96194503 A CN96194503 A CN 96194503A CN 1188409 A CN1188409 A CN 1188409A
- Authority
- CN
- China
- Prior art keywords
- micatin
- antifungal
- chloride
- trichophyton
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 23
- 239000003429 antifungal agent Substances 0.000 title 1
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 22
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 17
- 239000012871 anti-fungal composition Substances 0.000 claims abstract description 8
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 53
- 229960001378 dequalinium chloride Drugs 0.000 claims description 40
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 claims description 40
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 18
- 150000002460 imidazoles Chemical class 0.000 claims description 18
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims description 11
- 229960004022 clotrimazole Drugs 0.000 claims description 11
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 8
- 229960001950 benzethonium chloride Drugs 0.000 claims description 8
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229960002206 bifonazole Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229960002509 miconazole Drugs 0.000 claims description 5
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 4
- 229960003913 econazole Drugs 0.000 claims description 4
- XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 239000003814 drug Substances 0.000 abstract description 20
- 241000223238 Trichophyton Species 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 abstract 1
- 229960005040 miconazole nitrate Drugs 0.000 abstract 1
- 229940101563 micatin Drugs 0.000 description 42
- 230000001954 sterilising effect Effects 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 18
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 17
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 9
- 229960004889 salicylic acid Drugs 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 241000222122 Candida albicans Species 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 7
- -1 tincture Substances 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 229940095731 candida albicans Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 4
- 229940043276 diisopropanolamine Drugs 0.000 description 4
- 229960003645 econazole nitrate Drugs 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229960004194 lidocaine Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 230000004763 spore germination Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CRKGMGQUHDNAPB-UHFFFAOYSA-N Sulconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CSC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 CRKGMGQUHDNAPB-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 244000000008 fungal human pathogen Species 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960002894 oxiconazole nitrate Drugs 0.000 description 1
- WVNOAGNOIPTWPT-NDUABGMUSA-N oxiconazole nitrate Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)/CN1C=NC=C1 WVNOAGNOIPTWPT-NDUABGMUSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004718 sulconazole nitrate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An antifungal composition including an imidazole-type antifungal compound and a quaternary ammonium salt is a medicament having a far more potentiated activity of miconazole nitrate and a higher therapeutic effect, and is effective against both Trichophyton and Candida.
Description
The present invention relates to a kind of antifungal.Relate to a kind of being characterised in that in more detail and contain the antifungal compositions that imidazoles is antifungal and quaternary ammonium salt.
Imidazoles as the antifungal main flow is that antifungal is the medicament that has imidazole radicals in its chemical constitution in the world.Mainly be to show antibacterial action by the cell membrane that destroys fungus.
As imidazoles is antifungal, and clotrimazole, micatin, econazole nitrate, bifonazole, Oxiconazole Nitrate, sulconazole nitrate, tioconazole etc. are as the conversion OTC composition of (Switch OTC) and known by people.
Clotrimazole only uses in the medicine for external use field, is effective to Trichophyton, Candida etc.When being used for healthy skin, thinking does not almost have to absorb in the body, but thinks that partial side effect is arranged, as the excitement of skin, rubescent, come out in a rash etc., consider these phenomenons with to the direct stimulation of skin or irritated act on relevant.
Bifonazole demonstrates the effect identical with clotrimazole.It is effective being considered to multiple human pathogenic fungi.With other imidazoles is that antifungal is compared, and thinks that the percutaneous permeability of its outer time spent is good, storing property of the medicament height in skin histology.With clotrimazole the excitement of skin, rubescent, partial side effect such as come out in a rash are arranged equally.
Micatin, econazole nitrate, when Trichophyton, Candida, Cryptococcus etc. were also demonstrated antimicrbial power and are used for healthy skin, thinking did not almost have to absorb in the body; Usually when external is used, do not have the side effect of general, but think and have the side effect same in the part with clotrimazole.
So-called quaternary ammonium salt is meant the material that belongs to quaternary ammonium salt as cationic surfactant.Benzethonium chloride, benzalkonium chloride, dequalinium chloride etc. are for example arranged.Be considered to bring into play bactericidal action because the cation-adsorption of quaternary ammonium salt on the surface of thalline, enters in the cell then so that the protein in the pair cell influences
Benzethonium chloride, benzalkonium chloride demonstrate sterilizing power to gram-bacteria, fungus, but as side effect to the skin life-time service time, can occur stimulating, come out in a rash, allergic symptom such as titillation this be known.
Dequalinium chloride is considered to antibacterial (particularly staphylococcus aureus, the sterilization of haemolysis type streptococcus), fungus are demonstrated sterilizing power.Mainly be engaged in antibacterial in the oral cavity, anti-toothache preparation, the anti-alveolysis agent.
By imidazoles is that antifungal and quaternary ammonium salt cooperate the medicament that forms still not know, and is antifungal and salicylic acid or benzoic example but disclose the cooperation imidazoles in No. the 2208598th, the open communique of British patent.
The general vitamin B1 deficiency that is difficult to healing, necessary long-term coating, winter, beriberic symptom can not be effected a radical cure fully, can only slow down the activity of bacterium, therefore wished to develop the high medicament of therapeutic effect.In addition, beriberic morbidity is microbial by Trichophyton or beads, and the difference between Trichophyton and the candidiasis is use microscopic examination by special doctor, can only differentiate by the cultivation of bacterium since differentiate difficulty so to both sides all efficacious agents be important.As previously mentioned, imidazoles is that antifungal has partial side effect, as the excitement of skin, rubescent, come out in a rash etc., thereby reduce that to work hard aspect side effect also be necessary reducing their use levels in medicament.
Present inventors have the medicament of fungicidal effectiveness and improve its usability Trichophyton and candidiasis both sides with exploitation is purpose, is that antifungal and the medicament with useful effect have carried out various screenings for selecting imidazoles.Found that certain quaternary ammonium salt has the reinforced effects that multiplies each other aspect sterilizing power, and finished the present invention based on this discovery.
That is to say, the present invention relates to a kind of antifungal compositions, it is characterized in that containing imidazoles is antifungal and quaternary ammonium salt.
Imidazoles is in the antifungal, and preferred material is miconazole, econazole, clotrimazole, bifonazole etc.And the salt of miconazole, econazole also can use.Especially nitrate is widely used.
So-called quaternary ammonium salt is meant the material that belongs to quaternary ammonium salt as cationic surface work agent, and preferred quaternary ammonium salt has benzethonium chloride, benzalkonium chloride, dequalinium chloride etc. among the present invention.
Imidazoles is that the use level of antifungal is 0.2~1 weight %, preferred 0.5~1 weight %.
The use level of quaternary ammonium salt is 0.1~1 weight %, preferred 0.5~1 weight %, and for example the use level of benzethonium chloride is 0.5~1.0 weight %, the use level of benzalkonium chloride is 0.1~1 weight %, preferred 0.5~1 weight %.
Imidazoles with respect to 1 weight portion is an antifungal, preferably cooperates quaternary ammonium salt 0.1~1 weight portion, more preferably cooperates 0.1~0.5 weight portion.
In the effective ingredient of the present invention, can mix known additive etc. as required, available usual method is made external preparation such as liquor, detergent, Emulsion, tincture, ointment, cream, aqueous gel, oil-base gel agent, aerosol.
As water soluble ingredient, can enumerate propylene glycol, 1,3 butylene glycol, glycerol, ethanol, polyethylene glycols etc.
As the oiliness composition, can enumerate diisopropyl adipate, stearoyl alcohol, spermol, three decanes, medium chain triglyceride etc.
As polymer substance, can enumerate carboxy vinyl polymer, methylcellulose etc.
As the pH regulator agent, can enumerate organic amines such as inorganic salt, diisopropanolamine (DIPA) such as sodium hydroxide etc.
As antioxidant, can enumerate dibenzylatiooluene (BHT), Butylated hydroxyanisole (BHA), alpha-tocopherol, arabo-ascorbic acid, sodium pyrosulfite etc.
As coloring agent, can enumerate titanium oxide etc.
As surfactant, for example can enumerate polyoxyethylene hardened castor oil, sorbitan monostearate, sorbitan monopalmitate, glyceryl monostearate, sorbitan list dodecylate, polyoxyethylene polyoxypropylene block copolymer, polysorbate class, sodium lauryl sulfate, sucrose fatty acid ester, lecithin etc.
As stabilizing agent, can enumerate EDTA-2Na etc.
In addition, the particularly preferred antifungal compositions of the present invention is to be that epiphyte pharmaceutical and dequalinium chloride are the antifungal compositions of feature to contain imidazoles.
If further research skin irritation, preparationization etc. from the quaternary ammonium salt of the bactericidal effect of confirming to multiply each other, as shown in table 1, dequalinium chloride is optimum.
Table 1
The chemical compound title is suitable for the preparation skin irritation |
Benzalkonium chloride zero △ dequalinium chloride 00 |
Among the present invention, effective use level of micatin is 0.2~1 weight %, preferred 0.5~1 weight %.
Effective use level of dequalinium chloride is 0.05~0.5 weight %, preferred 0.1~0.5 weight %.
With respect to 1 weight portion micatin dequalinium chloride is 0.1~1 weight portion, preferred 0.1~0.5 weight portion.
Medicament of the present invention is the potent antifungal that a kind of bactericidal effect is enhanced.
Below enumerate the test example and specify effect of the present invention.
Test example 1
(1) strains tested
Strains tested adopts following mushroom.
Trichophyton purpureatum (Trichophyton rubrum)
Trichophyton mentagrophytes (Trichophyton mentagrophytes)
(2) preparation method of spore liquid
On the inclined-plane of the developmental tube that 1/10 Sa Shi agar culture medium is housed, implant for the examination bacterium, cultivated for 3~4 weeks in 28 ℃.Cultivate the back and take out thalline, it is transplanted on bead is housed and 10ml contains in the conical flask (100ml volume) of the normal saline solution of 0.1%Tween80, vibrate after 1 hour,, become spore liquid through the tampon filtration with the sterilization spatula.The spore liquid stored refrigerated was used in 1 month
(composition of 1/10 Sa Shi agar culture medium)
Glucose 4.0g, peptone 1.0g, potassium dihydrogen phosphate (anhydrous) 1.5g, magnesium sulfate (7 hydrate) 1.0g, Chile saltpeter 1.0g, agar 20.0g, distilled water 1000ml.
(3) preparation of reagent agent
Reagent agent is used micatin, benzalkonium chloride, dequalinium chloride, benzethonium chloride and salicylic acid; Use DMSO with solvent, and be adjusted to experimental concentration and make 2 times of dilution series as dissolving, dilution.
(4) test method
After will also solidifying through the mixed that the reagent agent and the Sa Shi agar culture medium (Rong Yan) of dilution are pressed 1: 99, inoculate about 10
5The spore liquid of individual/milliliter.In 28 ℃ of cultivations 5 days, confirm to have aseptic growth.
DMSO concentration is defined as does not have below 1% of influence to spore-germination.
(5) judgement and calculating formula
The judgement of the effect that multiplies each other is to confirm that the minimum drug concentration (MIC: minimal inhibitory concentration, μ g/ml) that bacterium no longer grows calculates FIC index (Fractional Inhihltory Concentration indcx) when cultivate finishing
(calculating formula) C index=a/a
0+ b/b
0
A: the MIC of two stupid imidazoles of chlorine of nitric acid and the micatin of reagent agent and time spent:
a
0: the MIC when micatin uses separately;
B: the MIC of the reagent agent of micatin and reagent agent and time spent;
b
0: the MIC when reagent agent is used separately.(judgement) has or not combined effect according to following standard determination
>2: antagonism
Below 2~and greater than 1: summation action
Below 1: synergism
(6) result
Judge the FIC exponential quantity of the effect that multiplies each other, through consider antibacterial evaluation and 1 screening back setting below 1.0 for having the effect of multiplying each other.Its result is as shown in table 2, confirms that nearly all medicament all has the addition or the effect that multiplies each other:
Table 2
FIC indexation compound title trichophyton purpureatum Trichophyton mentagrophytes |
Benzethonium chloride 0.49 0.55 benzalkonium chloride 0.12 0.26 dequalinium chloride 0.47 0.68 salicylic acid 0.44 0.72 |
Test example 2 (1) strains testeds
Strains tested adopts following mushroom.
Trichophyton purpureatum (Trichophyton rubrum)
The preparation method of Trichophyton mentagrophytes (Trichophyton mentagrophytes) (2) spore liquid
Press the preparation with quadrat method preparation (3) reagent agent with the routine l of test
Reagent agent is used micatin, econazole nitrate, clotrimazole, bifonazole and dequalinium chloride; Use DMSO and be adjusted to experimental concentration as dissolving, retarder thinner and make 2 times of dilution series.(4) test method
By carrying out with quadrat method with test example 1.(5) judgement and calculating formula
By calculating with quadrat method with test example 1 and judging.(6) result
The results are shown in the table 3.
Table 3 imidazoles be antifungal and
The effect that multiplies each other of dequalinium chloride
FIC indexation compound title trichophyton purpureatum Trichophyton mentagrophytes |
Micatin 0.32 0.55 econazole nitrate 0.63 0.63 clotrimazole 0.38 1.25 bifonazole 0.25 0.14 |
Its result is as shown in table 3, except the effect of clotrimazole to Trichophyton mentagrophytes, all demonstrates the strong effect that multiplies each other with dequalinium chloride.
Can be clear that according to above result owing to making up the effect that multiplies each other that causes with dequalinium chloride, not only micatin has, and imidazoles is that antifungal all has this effect.
Test example 3 (1) strains testeds
Strains tested adopts following mushroom.
Trichophyton purpureatum (Trichophyton rubrum)
The preparation method of Trichophyton mentagrophytes (Trichophyton mentagrophytes) (2) spore liquid
By preparing with test example 1 same procedure.(3) preparation of reagent agent
Reagent agent is used micatin (MCZ), salicylic acid, benzalkonium chloride (BAC) and dequalinium chloride (DQ); Use DMSO and be adjusted to experimental concentration as dissolving, retarder thinner and make 2 times of dilution series (4) test method
In 20mM phosphate buffer (pH6.5) 20ml of sterilization after filtration, add each medicament 100 μ l, after mixing according to 10
5The concentration of individual/milliliter adds spore liquid (common 50~200 μ l), and stirs it.In 30 ℃ of insulations and measure the survival spore count of the 1st day, the 2nd day and the 3rd day.In addition, be defined in can be not influential below 1% to spore-germination for DMSO concentration.(5) assay method of survival spore count
Survival spore count in spore liquid and the experimental liquid is by using sterilization normal saline solution or LP diluent (DAIGO) to make 10 times of dilution series, each diluent 50 μ l is spread upon on the previously prepared Sa Shi agar culture medium (Rong Yan), under 28 ℃ of situations, cultivate more than 4 days at trichophyton purpureatum, cultivate under the situation of Trichophyton mentagrophytes more than 3 days, calculate the spore count of surviving in spore liquid or the experimental liquid according to the clump count that occurs.(6) the multiply each other judgement of effect
According to document (Antimicrobial Agents and Chemotherapy Feb.1977, p.225-228), if separately the time and and the difference of the survival spore count of time spent be about 2 more than the order of magnitude then be judged as the effect that multiplies each other
The killing curve of (result of the test) (1) micatin
Confirmed the micatin sterilizing power in sterilization normal saline solution (pH) separately.Its result as shown in Figure 1, sterilizing power increases along with concentration.The easy 3.13 μ g/ml concentration of judging the bactericidal effect that multiplies each other are selected in the test of combined effect.(2) killing curve of medicament and time spent
Table 4 illustrates the interior maximum proportioning of border standard of each medicament and micatin.
Table 4
The chemical compound title | Proportioning * |
Salicylic acid benzalkonium chloride dequalinium chloride | ????10 ????1 ????0.5 |
*) use level of micatin is defined as under 1 the situation
And the sterilizing power of time spent is confirmed by add each medicament by maximum proportioning separately in the micatin of 3.13 μ g/ml.
As shown in Figure 2, and the sterilizing power of time spent is except salicylic acid, and all being confirmed to be has enhancing when using separately compared with micatin.
Below the effect of each medicament is gone through.
Salicylic result shown in Fig. 3.
Can't see sterilizing power when salicylic acid uses separately fully, and the sterilizing power of time spent when also just using separately with micatin about equally or below it.According to the exponential result of FIC of 1 screening, salicylic acid also can be inferred the bacteriostatic combined effect.
Fig. 4 illustrates the result of benzalkonium chloride
When benzalkonium chloride uses separately, confirm identically with the micatin effect under the situation of trichophyton purpureatum, under the Trichophyton mentagrophytes situation, have the sterilizing power higher than micatin, and the time spent two kinds of bacterium all detecting below the boundary at the 1st day.
Fig. 5 illustrates the result of dequalinium chloride
Sterilizing power when dequalinium chloride uses separately equates with micatin, in case and usefulness, at the 2nd day promptly in that to detect boundary as follows
The multiply each other judgement of effect of sterilizing power, according to document (Antimicrobial Agents andChemotherapy, Feb 1977, p. 225~228), if in the time of separately and and the difference of the survival spore count of time spent be 2 more than the order of magnitude then be judged as and produce effect, therefore benzalkonium chloride and dequalinium chloride are judged as and have the sterilizing power that multiplies each other.
Test example 4 (1) strains testeds
Strains tested adopts following mushroom
Candida albicans (Candida albicans)
The preparation method of staphylococcus aureus (Staphylococcus aureus) (2) bacterium liquid
Candida albicans was cultivated 24 hours in 28 ℃ in Sa Shi agar culture medium (Rong Yan), according to about 10
6Individual/milliliter be suspended in like that the sterilization normal saline solution in, with it as bacterium liquid.Staphylococcus aureus was cultivated 18 hours in 37 ℃ in sulfa drug sensitization test culture medium (Rong Yan), according to about 10
6Individual/milliliter be suspended in like that the sterilization normal saline solution in, with it as bacterium liquid.(3) preparation of reagent agent
Reagent agent is used micatin and dequalinium chloride; Use DMSO and be adjusted to experimental concentration as dissolving, retarder thinner and make 2 times of dilution series.(4) test method
After will also solidifying through the mixed that the reagent agent and the Sa Shi agar culture medium (Rong Yan) of dilution are pressed 1: 99, the bacterium liquid of inoculation Candida albicans.In 30 ℃ of cultivations 2 days, confirm to have aseptic growth.
After will also solidifying through the mixed that the reagent agent and the Mueller-Hinton agar culture medium (Rong Yan) of dilution are pressed 1: 99, inoculate full Staphylococcus aureus.In 30 ℃ of cultivations 24 hours, confirm to have aseptic growth (5) to judge and calculating formula
By calculating with quadrat method and judgement (6) result with test example 1
Table 5 illustrates its result
Table 5
Strains tested FIC index |
Candida albicans 0.11 |
Staphylococcus aureus 0.75 |
Owing to micatin and dequalinium chloride cooperate the effect that multiplies each other that produces, even also can obtain affirmation to Candida albicans and staphylococcus aureus.
Test example 5
Carried out and the same test of test example 3 about the influence of micatin and the match ratio of dequalinium chloride and time spent (1: 0.12~1.00), Fig. 6 illustrates its result of the test.
Consequently, and the sterilizing power of time spent when match ratio be that 1~0.12 sterilizing power when using separately than micatin and dequalinium chloride when above is stronger, confirm also to have the effect of multiplying each other.
Test example 6: the influence of lecithin
As the base of cream and the lecithin that uses, be that [Shiguan is loyal first-class for the inactivator of antibacterial such as quaternary ammonium salt as everyone knows, No. 91 (1973) are reported by health test institute], so study for its influence that effect that multiplies each other of micatin and dequalinium chloride is brought.
Lecithin concentration is under the situation that micatin uses separately, be adjusted to match ratio (micatin: lecithin=1: 0.5), when using separately, dequalinium chloride reaches and micatin and time spent, lecithin concentration is defined as 1.57 μ g/ml, carries out and the same test of test example 3.
Its result shows that the concentration of these lecithin is not influence fully.
Below enumerate embodiment and specify the present invention
(cream prescription example)
Micatin 100g
Lignocaine 200g
Dequalinium chloride 10g
Polyoxyethylene sorbitan monostearate 400g
Sorbitan monostearate 200g
1,3 butylene glycol 1,500g
MCT Oil 1,500g
Glyceryl monostearate 250g
EDTA-2Na??????????????????????10g
Purified Water total amount to 10,000g
(manufacture method)
At water-phase component (1,3-butanediol, EDTA-2Na, dequalinium chloride, Purified Water) the middle oil-phase component (micatin, lignocaine, sorbitan monostearate, MCT Oil, glyceryl monostearate, polyoxyethylene sorbitan monostearate) that adds, after heating, mixture makes cream 10,000g by well-established law.
(liquor prescription example)
Nitric acid acid miconazole 100g
Dequalinium chloride 20g
Glycyrrhizic acid dipotassium 50g
BHT??????????????????????????5g
Ethanol 5,000g
Purified Water total amount to 10,000ml
(manufacture method)
After being dissolved in medicament in the ethanol, adding Purified Water, to make its total amount be 10,000ml.
(gel cream prescription example)
Micatin 100g
Dequalinium chloride 20g
Lignocaine 200g
Polyoxyethylene sorbitan monostearate 100g
Propylene glycol 1,000g
Liquid paraffin 500g
Stearoyl alcohol 100g
Carboxy vinyl polymer 50g
Diisopropanolamine (DIPA) 100g
Purified Water total amount to 10,000g
(manufacture method)
With oil-phase component (micatin, lignocaine, dequalinium chloride, polyoxyethylene sorbitan monostearate, liquid paraffin, the stearoyl alcohol) dissolving of heating, cool to room temperature.Then carboxy vinyl polymer is dissolved in the propylene glycol, places, make the carboxy vinyl polymer swelling in room temperature.Above-mentioned oil phase and water at room temperature stirred make gel cream.
(aerosol prescription)
Stock solution: micatin 50g
Dequalinium chloride 5g
Glycyrrhizic acid dipotassium 25g
Ethanol 2500g
Purified Water 5000ml
Propellant: LPG 5000ml
(manufacture method)
After the stock solution that will dissolve the principal agent composition in the base of ethanol, Purified Water is filled in the container, mounted valve, aerosol is made in the filling spray agent.
Following simple declaration accompanying drawing.
Fig. 1 illustrates the sterilizing power of micatin to trichophyton purpureatum (A) and Trichophyton mentagrophytes (B).Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit logarithm (1 expression 10 just, of viable count/milliliter
1Individual/milliliter, 2 expressions 10
2Individual/milliliter, 3 expressions 10
3Individual/milliliter, 4 expressions 10
4Individual/milliliter).
Fig. 2 illustrates each medicament and the time spent sterilizing power to trichophyton purpureatum (A) and Trichophyton mentagrophytes (B).Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit the logarithm of viable count/milliliter
MCZ represents micatin, and BAC represents benzalkonium chloride, and DQ represents dequalinium chloride.
Fig. 3 illustrates salicylic acid and the time spent sterilizing power to trichophyton purpureatum (A) and Trichophyton mentagrophytes (B).Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit the logarithm of viable count/milliliter.
MCZ represents micatin
Fig. 4 illustrates benzalkonium chloride and the time spent sterilizing power to trichophyton purpureatum (A) and Trichophyton mentagrophytes (B).Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit the logarithm of viable count/milliliter.
MCZ represents micatin, and BAC represents benzethonium chloride.
Fig. 5 illustrates dequalinium chloride and the time spent sterilizing power to trichophyton purpureatum (A) and Trichophyton mentagrophytes (B).Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit the logarithm of viable count/milliliter.
MCZ represents micatin, and DQ represents dequalinium chloride.
Fig. 6 illustrates the result who studies for the influence of micatin and the match ratio of dequalinium chloride and time spent.Transverse axis represents to preserve natural law, and the longitudinal axis represents to deposit the logarithm of viable count/milliliter.MCZ represents micatin.
Claims (4)
1. antifungal compositions, it is characterized in that wherein containing imidazoles is antifungal and quaternary ammonium salt.
2. an antifungal compositions is characterized in that wherein containing (A) miconazole, econazole, clotrimazole or bifonazole, and (B) quaternary ammonium salt
3. an antifungal compositions is characterized in that wherein containing (A) miconazole, econazole, clotrimazole or bifonazole, and (B) benzethonium chloride, benzalkonium chloride or dequalinium chloride.
An antifungal with compositions, to it is characterized in that wherein containing imidazoles be antifungal and dequalinium chloride.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN96194503A CN1188409A (en) | 1995-06-07 | 1996-06-07 | Antifungal agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP140598/95 | 1995-06-07 | ||
CN96194503A CN1188409A (en) | 1995-06-07 | 1996-06-07 | Antifungal agent |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1188409A true CN1188409A (en) | 1998-07-22 |
Family
ID=5128674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN96194503A Pending CN1188409A (en) | 1995-06-07 | 1996-06-07 | Antifungal agent |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1188409A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100418536C (en) * | 2005-04-06 | 2008-09-17 | 河南省眼科研究所 | Ophthalmic pharmaceutical composition for resisting fungus |
CN104606278A (en) * | 2014-12-31 | 2015-05-13 | 张洛燕 | Preparation method of external Zimiexuan tincture |
CN108186639A (en) * | 2018-02-28 | 2018-06-22 | 扬子江药业集团广州海瑞药业有限公司 | A kind of pharmaceutical composition of SS 717 |
-
1996
- 1996-06-07 CN CN96194503A patent/CN1188409A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100418536C (en) * | 2005-04-06 | 2008-09-17 | 河南省眼科研究所 | Ophthalmic pharmaceutical composition for resisting fungus |
CN104606278A (en) * | 2014-12-31 | 2015-05-13 | 张洛燕 | Preparation method of external Zimiexuan tincture |
CN108186639A (en) * | 2018-02-28 | 2018-06-22 | 扬子江药业集团广州海瑞药业有限公司 | A kind of pharmaceutical composition of SS 717 |
CN108186639B (en) * | 2018-02-28 | 2019-03-05 | 扬子江药业集团广州海瑞药业有限公司 | A kind of pharmaceutical composition of SS 717 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1355699A (en) | Antifungal compositions | |
CN1261426C (en) | Iodobenzopyrran-4-one derivatives having fungicidal activity | |
RU2419429C2 (en) | Pharmaceutical composition for external application | |
EP0170139B1 (en) | Antifungal composition | |
CN1066170A (en) | As the dihydroxymethyl 2 of biocide and preservative, 5-piperazinedione | |
CN1096860C (en) | Topical ketoconazole compositions | |
CN1194582A (en) | Anti fungal agent, compound therefor, process for producing the same | |
CN1087913A (en) | Rapamycin derivative | |
CN1206916C (en) | Fungicide mixtures based on amide compounds and azoles | |
CN1035435A (en) | Be used for partial metronidazol preparation and treatment application thereof | |
CN1893919A (en) | Endoparasiticidal agents for topical application | |
CN100339378C (en) | 6-2-(2-halogen-4-alkoxypenyl)-triazo-pyrimidine of killing fungus | |
CN101028229A (en) | Cosmetics based on nitric oxide | |
CN1308067A (en) | Preparation method of methylol hydantoin composite with low content of free formaldehyde | |
CN1093401C (en) | Active oxygen, free radical scavenger | |
CN1092959C (en) | Pharmaceutical composition contg. tiagabine hydrochloride and process for its preparation | |
CN1209972C (en) | Sterilization formulation and wet tissue, preparation method and use | |
CN1188409A (en) | Antifungal agent | |
CN1813724A (en) | Liranaftate paste and its preparing method | |
CN1684662A (en) | Cleansing composition containing antifungal agent and antibacterial agent | |
CN1238353C (en) | Amino acid ester containing azole antifungals | |
CN1159009C (en) | pharmaceutical use of benzoic acid derivatives | |
CN1166362C (en) | Solution agent of antiallergi medicine contg. levocetirizine | |
CN1182739A (en) | N-benzylazolium derivatives | |
FR2466988A1 (en) | SYNERGISTIC ANTIFUNGAL COMPOSITIONS USEFUL IN PARTICULAR AGAINST CANDIDA ALBICANS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1030419 Country of ref document: HK |